Oral weight-loss drugs from Structure Therapeutics and others lead the agenda ahead of ObesityWeek 2026. We explain the small-molecule science and why a pill changes the market.

CHEST has published a six-step framework for building lung nodule programs, from detection to diagnosis, including validated biomarker testing. We explain how it works.

Evidence continues to build for continuous glucose monitors in type 2 diabetes: patients using CGMs spend around five more hours a day in healthy blood-sugar range. The data story behind the numbers.

A striking survey figure — 83% of CFOs say most of their AI projects have not produced measurable results — captures enterprise AI’s awkward adolescence. The successes share identifiable traits.

As AI features commoditise, cloud pricing feels the heat — and value migrates to integration, oversight and trust.

Every outbreak warning rests on epidemiologists, labs and data engineers whose continuity a stalled contract puts at risk.

Most papers challenging the ultra-processed food definition have industry-linked authors, a new analysis reports. A cautious guide to the finding and its limits.

Up to $21 billion of Japanese investment is headed for GlobalFoundries plants in New York. A clear look at the factories, the jobs and the strategy behind the plan.